BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Setidegrasib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Setidegrasib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07395024-2183@assetmemo.bio
DTSTAMP:20261121T004511Z
DTSTART;VALUE=DATE:20270502
DTEND;VALUE=DATE:20270503
SUMMARY:Setidegrasib: Phase 1 readout est. (NCT07395024)
DESCRIPTION:Setidegrasib\, phase 1.\nStudy: A Study to Learn How Fluconazol
 e\, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 i
 n Healthy Adults\nEstimated primary completion: 2 May 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/setidegrasib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07395024
URL:https://assetmemo.bio/drug/setidegrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483983-2183@assetmemo.bio
DTSTAMP:20261121T004511Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Setidegrasib: Phase 2 readout est. (NCT07483983)
DESCRIPTION:Setidegrasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non
 -small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC
 )\, With Biomarker Analysis to Characterize Response/Resistance\nEstimated
  primary completion: September 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/setidegrasib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07483983
URL:https://assetmemo.bio/drug/setidegrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05382559-2183@assetmemo.bio
DTSTAMP:20261121T004511Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Setidegrasib: Phase 1 readout est. (NCT05382559)
DESCRIPTION:Setidegrasib\, phase 1.\nStudy: A Study of ASP3082 in Adults Wi
 th Advanced Solid Tumors\nEstimated primary completion: 31 December 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/setidegrasib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05382559
URL:https://assetmemo.bio/drug/setidegrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07409272-2183@assetmemo.bio
DTSTAMP:20261121T004511Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Setidegrasib: Phase 3 readout est. (NCT07409272)
DESCRIPTION:Setidegrasib\, phase 3\, Pancreatic Ductal Adenocarcinoma.\nStu
 dy: A Study to Evaluate the Effectiveness and Safety of Setidegrasib\, Giv
 en With Either mFOLFIRINOX or NALIRIFOX Chemotherapies\, in People With Pa
 ncreatic Cancer\nEstimated primary completion: 31 August 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/setidegrasib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07409272
URL:https://assetmemo.bio/drug/setidegrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07566052-2183@assetmemo.bio
DTSTAMP:20261121T004511Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Setidegrasib: Phase 3 readout est. (NCT07566052)
DESCRIPTION:Setidegrasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study to Compare Setidegrasib (ASP3082) With Docetaxel\, in People With No
 n-small Cell Lung Cancer With a KRAS G12D Mutation\nEstimated primary comp
 letion: 30 June 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /setidegrasib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07566052
URL:https://assetmemo.bio/drug/setidegrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
